AIM
DMK

Acrospire Investment Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Acrospire Investment Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10
Closed -$3K – 2614
2017
Q1 		$3K Sell
10
-60
-86% -$15.1K ﹤0.01% 2090
2016
Q4 		$15K Buy
+70
New +$14K 0.01% 1865

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SGS
Sterling Global Strategies Carlsbad, California $18M AUM 11.58% 1-Year Est. Return

Acrospire Investment Management's DMK Position: Q2 2017 in Review

Acrospire Investment Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2017, closing a stake of 10 shares — an estimated $3K sold.

Acrospire Investment Management first reported a position in DMK in Q4 2016 and held it in 2 quarters. The position peaked at $15K in Q4 2016. 44 funds tracked by Wall St. Rank hold DMK as of Q2 2017.

  • Acrospire Investment Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 10 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2017, an estimated $3K.
  • Acrospire Investment Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $15K in Q4 2016.
  • 44 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.